Here are three things to know:
1. The iFuse procedure will be added to the List of Refundable Products and Services in France following the favorable opinion of the National Commission for the Evaluation of Medical Devices and Health Technologies.
2. Exclusive coverage is effective for an initial five-year period.
3. The commission recommends brand name registration for the iFuse Implant System for second-line treatment of SI joint dysfunction caused by SI joint disruption or degenerative sacroiliitis in patients who do not respond to conservative treatment.
More articles on MIS:
Cervical fusion market surges 27% in 2 years: 5 takeaways
Physician Partners of America adopts new variety of laser spine surgery
Life Spine to demonstrate micro-invasive systems: 3 notes
